December 21, 2023 News by Patricia Inacio, PhD Dosing begins in Phase 2a trial of foralumab nasal spray for SPMS Tiziana Life Sciences has dosed the first patient in a Phase 2a clinical trial testing itsĀ foralumab nasal spray in people with nonactive secondary progressive multiple sclerosisĀ (SPMS). The trial will include about 54 participants, enrolled across six clinical sites. Patients will be randomly assigned to receive one of two…
May 15, 2023 News by Margarida Maia, PhD 1st group of healthy volunteers dosed in Phase 1 trial of ‘Lucid-MS’ FSD Pharma has completed dosing in the first group of healthy volunteers enrolled in its Phase 1 clinical trial testing Lucid-21-302, an oral medication candidate for all types of multiple sclerosis (MS). The medication, also known as Lucid-MS, was first given to a sentinel subject ā one…
January 26, 2023 News by Patricia Inacio, PhD Patient Dosing Starts in MS Phase 2 Clinical Trial of Oral SAR443820 Patient dosing has begun in a Phase 2 trial testing Denali Therapeutics‘ investigational oral RIPK1 inhibitor SAR443820 in people with multiple sclerosis (MS). The clinical trial (NCT05630547) seeks to enroll about 168 patients, age 18ā60, with either relapsing-remitting MS (RRMS), active and nonactive secondary progressive…
July 21, 2022 Columns by Benjamin Hofmeister A Friend Under the Skin: My Intrathecal Baclofen Pump In my last column, I mentioned that I had an intrathecal baclofen pump. Iād make a bad pun, but I donāt have it in me. Spasticity, spasms, and hyperreflexivity were some of my first symptoms, which steadily got worse as my multiple sclerosis (MS) progressed.
May 3, 2022 News by Marisa Wexler, MS Tysabri Every 6 Weeks Found as Effective as Standard 4-week Dosing Tysabri (natalizumab) given every six weeks was found to be similarly effective as the standard four-week dosing schedule at stopping nervous system damage in people with relapsing-remitting multiple sclerosis (RRMS). That’s according to the full results of the Phase 3b NOVA clinical trial, which compared Tysabri dosing schedules…
October 15, 2021 News by Marisa Wexler, MS #ECTRIMS2021 ā Lower Relapse Rates Seen With Tysabri Than Ocrevus Editorās note: TheĀ Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13ā15. GoĀ here to see the latest stories from the conference. People withĀ …
June 10, 2021 News by Steve Bryson, PhD Gilenya’s Optimal Dose for RRMS Confirmed in Review of Clinical Trials Gilenya (fingolimod) at itsĀ approved 0.5 mg daily dose continues to be the optimal dose for peopleĀ with relapsing-remitting MS (RRMS), a systematic review of 11 clinical trials confirmed. A 0.25 mg/day dose, however, also showed improvement over placebo in MRI outcomes and patient satisfaction, the researchers noted, and further…
May 8, 2019 News by Marisa Wexler, MS #AANAM – Research Suggests Extended Interval Dosing of Tysabri Can Decrease Risk of PML New data suggests that treatment withĀ TysabriĀ (natalizumab) in an extended interval dosing regimen is associated with a significantly lower risk ofĀ progressive multifocal leukoencephalopathyĀ (PML) in patients with multiple sclerosis (MS), compared with the standard interval dosing. The data was presented byĀ Lana Zhovtis Ryerson, MD, on May 7 at the 2019Ā …